Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GelteqGELS +0.30%8 3-Year EBITDA Growth Rate is -19.00% as of Dec. 2025. GuruFocus rates GELS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, Gelteq ranks worse than 88.63% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -19.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -15.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gelteq was 5.00% per year. The lowest was -36.80% per year. And the median was -19.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Gelteq 3-Year EBITDA Growth Rate Related Terms
GELS vs APUS, INM, YCBD: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gelteq's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelteq 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gelteq's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gelteq's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -19.00% mean?
Gelteq (GELS) has a 3-Year EBITDA Growth Rate of -19.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gelteq and its competitors. According to the industry distribution chart, Gelteq ranks #717 out of 809 companies in the Drug Manufacturers industry, placing it in the top 88.6%.
Is Gelteq's 3-Year EBITDA Growth Rate too high?
Gelteq's current 3-Year EBITDA Growth Rate is -19.00%. Based on the distribution chart, Gelteq ranks #717 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gelteq has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's 3-Year EBITDA Growth Rate compare to APUS and INM?
According to the Drug Manufacturers industry distribution chart, Gelteq ranks #717 out of 809 companies for 3-Year EBITDA Growth Rate. This places Gelteq in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gelteq and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelteq's current 3-Year EBITDA Growth Rate is -19.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current 3-Year EBITDA Growth Rate of -19.00%. The current 3-Year EBITDA Growth Rate is -19.00%. Gelteq's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Gelteq (GELS), the current 3-Year EBITDA Growth Rate is -19.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
8GF Score
Get the complete analysis for GELS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GELS has been successfully added to your 
